AI assistant
Novacyt Director's Dealing 2020
1557_dirs_2020-11-11_d0fca7d9-b5d2-40c3-b050-f76b39a94e68.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 9833E
Novacyt S.A.
11 November 2020
Novacyt S.A.
("Novacyt" or the "Company")
Director/PDMR Shareholding
Paris, France and Camberley, UK - 11 November 2020 - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on 10 November 2020, Edwin Snape, a Non-Executive Director of the Company, purchased 1,080 ordinary shares of €1/15 each in the Company at a price of £7.15 per share. Following the purchase, Mr Snape is interested in 17,919 ordinary shares representing 0.025% of the issued share capital.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1.
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Edwin Snape - Non-Executive Director
2.
Reason for the Notification
a)
Position/status
See 1(a) - classified as a PDMR of the Company
b)
Initial notification/ Amendment
Initial Notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Novacyt S.A.
b)
LEI
213800BWAC2BF295EG28
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the Financial instrument, type of instrument
ordinary shares of €1/15 each
Identification code
FR0010397232
b)
Nature of the transaction
Acquisition of Ordinary Shares
c)
Price(s) and volume(s)
| Price | Volume |
| £7.15 | 1,080 |
d)
Aggregated information:
· Aggregated volume
· Price
N/A Single transaction as above
| Price | Volume |
| £7.17 | 1,080 |
e)
Date of the transaction
10 November 2020
f)
Place of the transaction
AIM
Contacts
Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1276 600081
SP Angel Corporate Finance LLP (Nominated Adviser and Broker)
Matthew Johnson / Charlie Bouverat (Corporate Finance)
Vadim Alexandre / Rob Rees (Corporate Broking)
+44 (0)20 3470 0470
Numis Securities Limited (Joint Broker)
Freddie Barnfield / James Black
+44 (0)20 7260 1000
FTI Consulting (International)
Victoria Foster Mitchell / Mary Whittow
+44 (0)20 3727 1000
[email protected] / [email protected]
FTI Consulting (France)
Arnaud de Cheffontaines
+33 (0)147 03 69 48
About Novacyt Group
The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company's lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.
For more information please refer to the website: www.novacyt.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHGPGQAGUPUGUG